This is the authors' abstract. We don't add key points for this paper.
PrEP is protective against HIV infection across populations, presents few significant safety risks, and there is no evidence of behavioral risk compensation. The effective and cost-effective use of PrEP will require development of best practices for fostering uptake and adherence among people at substantial HIV risk.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fonner et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: